Why Septerna, Inc.’s (SEPN) Stock Is Up 6.36%
As of Tuesday, August 11, Septerna, Inc.’s SEPN share price has surged by 6.36%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Septerna, Inc.’s (SEPN) Stock Is Up 16.71%
As of Tuesday, August 11, Septerna, Inc.’s SEPN share price has surged by 16.71%, which has investors questioning if this is right time to sell.Tudor Pop
What You Need to Know About Septerna, Inc.'s Q3 Earnings
Septerna, Inc.'s fiscal Q3 earnings report was released on Monday, August 10. Let's dive in to see if (SEPN) missed or beat analyst's expectations.Jenna Brashear
Is Septerna, Inc. (SEPN) Overvalued?
We dive into why Septerna, Inc. (SEPN) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Septerna, Inc.’s (SEPN) Stock Is Up 5.33%
As of Tuesday, August 04, Septerna, Inc.’s SEPN share price has surged by 5.33%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | SEPN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,904.0 | $618.0 | 53% |
|
| Shares Out (Mil) | 45.0 | 44.8 | 45% |
|
| Institutional Ownership | 95.2% | 85.3% | 67% |
|
| Float (Mil) | 26.4 | 47.4 | 34% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 609 | 390 | 61% |
|
| Price Change (52-week) |
273.2% | 68.6% | 98% |
|
| Growth | SEPN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.397) | ($1.187) | ($1.941) | |
| Month Ago EPS | ($0.552) | ($1.839) | ($2.659) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 1 | 2 | 0 | |
| Three Months Ago EPS | ($0.567) | ($1.892) | ($2.716) | |
| Year/Year Chg | 37.4% | 7.5% | 134.3% | |
| Financials | SEPN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $99 | $291 | 26% |
|
| Net Income (TTM) (Mil) | ($24) | ($11) | 22% |
|
| EPS (TTM) | ($0.542) | ($0.700) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | $106 | ($6) | 52% |
|
| Net Cash Flow (TTM) (Mil) | ($105) | $5 | 14% |
|
| Long-Term Debt (Q1) (Mil) | $20 | $6 | 33% |
|
| Enterprise Value (Q1) (Mil) | $1,735 | $450 | 47% |
|
| Valuation | SEPN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.82 | 2.78 | 77% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SEPN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.0% | 96% |
|
| Net Margin | (24.5%) | (2.3%) | 15% |
|
| ROA | (4.9%) | (22.4%) | 30% |
|
| ROE | (6.3%) | (20.2%) | 30% |
|
| Liabilities to Assets | 31.8% | 32.2% | 23% |
|
| F-Score | 6 | 3 | 67% |
|
Septerna, Inc. did not pass any screens on 8/20/2026.
